Progyny (NASDAQ:PGNY) Insider Sells $28,181.34 in Stock

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) insider Geoffrey Clapp sold 774 shares of the company’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $36.41, for a total transaction of $28,181.34. Following the sale, the insider owned 58,235 shares of the company’s stock, valued at $2,120,336.35. This represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Price Performance

Shares of PGNY opened at $36.18 on Monday. The stock has a market capitalization of $2.66 billion, a P/E ratio of 33.19, a PEG ratio of 1.66 and a beta of 0.97. The firm has a fifty day simple moving average of $28.48 and a two-hundred day simple moving average of $24.87. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $37.15.

Progyny (NASDAQ:PGNY – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The business had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. During the same quarter last year, the firm earned $0.15 EPS. The company’s revenue was up 8.9% on a year-over-year basis. Sell-side analysts expect that Progyny, Inc. will post 1.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PGNY. Barclays dropped their target price on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, August 12th. Jefferies Financial Group set a $33.00 price target on Progyny in a report on Tuesday, September 8th. Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Cantor Fitzgerald upped their price target on Progyny from $31.00 to $35.00 and gave the company an “overweight” rating in a research report on Thursday, November 5th. Finally, Citizens Jmp increased their price objective on Progyny from $33.00 to $38.00 and gave the stock a “market outperform” rating in a report on Thursday, November 5th. Eleven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Progyny has an average rating of “Moderate Buy” and a consensus price target of $35.33.

Get Our Latest Stock Analysis on Progyny

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Progyny during the 2nd quarter valued at $334,426,000. Bank of America Corp DE grew its position in shares of Progyny by 75.3% in the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after buying an additional 511,609 shares during the period. William Blair Investment Management LLC grew its position in shares of Progyny by 10.7% in the 3rd quarter. William Blair Investment Management LLC now owns 645,130 shares of the company’s stock worth $16,251,000 after buying an additional 62,178 shares during the period. Principal Financial Group Inc. increased its stake in shares of Progyny by 16.4% in the 1st quarter. Principal Financial Group Inc. now owns 554,916 shares of the company’s stock worth $9,422,000 after acquiring an additional 78,198 shares in the last quarter. Finally, Danske Bank A S bought a new position in shares of Progyny in the 2nd quarter worth about $15,243,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Company Profile

(Get Free Report)

Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.

Featured Articles

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.